Purpose <p>Bone marrow biopsy (BMB) is a common procedure for the diagnosis, staging, and evaluation of several hematological diseases. BMB often causes anxiety and pain even when local anesthesia (LA), premedication, or an equimolar mixture of oxygen and nitrous oxide (EMONO) are used. Hypnosis has emerged as a promising non-pharmacological method to reduce anxiety and pain during invasive procedures. QUALHYBOM, a prospective, multicenter, randomized, open-label study was conducted to assess whether adding hypnosis to LA (LA + H) could improve patient comfort during BMB compared to LA alone.</p> Method <p>QUALHYBOM included 180 BMB-naive patients with suspected or confirmed hematological disorders, randomized (LA group <i>n</i> = 91, LA + H group <i>n</i> = 89) from June 2023 to November 2024 across four French hematological departments. The primary endpoint was patient comfort rated on a scale from 0 (no comfort) to 10 (maximum comfort), evaluated immediately after the procedure. Secondary outcomes included pain, anxiety (before and after BMB), practitioner comfort, and use of EMONO.</p> Results <p>Patient groups were well-matched at enrolment. Median comfort scores were 9 vs. 5, pain scores 2 vs.6, and post-procedure scores 1 vs.5, in the LA + H vs.LA groups, respectively, both with <i>p &lt; </i>10⁻<sup>4</sup>. Finally, the operator comfort was higher (10 vs. 7), and EMONO requirement lower (3% vs. 29%) in the LA + H group, both with <i>p</i> &lt; 10⁻<sup>4</sup>.</p> Conclusion <p>These findings suggest that hypnosis significantly enhances patient comfort and key procedural parameters during BMB, warranting its consideration as addition to local anesthesia. Its integration into clinical practice may reduce the need for supplementary pharmacological interventions, including EMONO.</p> Trial registration <p>ClinicalTrials.gov Identifier NCT05178849.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Hypnosis associated with local anesthesia versus local anesthesia alone during bone marrow biopsy: a randomized, controlled, multicenter study, QUALHYBOM

  • Magali Granger,
  • Emmanuel Gyan,
  • Marlene Ochmann,
  • Brieuc Cherel,
  • Cecile Lermenier,
  • Aline Moignet,
  • Pierre Daufresne,
  • Stella Djoko,
  • Nicolas Vallet,
  • Martin Eloit,
  • Clemence Hameon,
  • Olivia Werle,
  • Audrey Fromenteau,
  • Anne-Laure Le Canderff,
  • Roch Houot,
  • Chloe Rousseau,
  • Bruno Laviolle,
  • Thierry Lamy

摘要

Purpose

Bone marrow biopsy (BMB) is a common procedure for the diagnosis, staging, and evaluation of several hematological diseases. BMB often causes anxiety and pain even when local anesthesia (LA), premedication, or an equimolar mixture of oxygen and nitrous oxide (EMONO) are used. Hypnosis has emerged as a promising non-pharmacological method to reduce anxiety and pain during invasive procedures. QUALHYBOM, a prospective, multicenter, randomized, open-label study was conducted to assess whether adding hypnosis to LA (LA + H) could improve patient comfort during BMB compared to LA alone.

Method

QUALHYBOM included 180 BMB-naive patients with suspected or confirmed hematological disorders, randomized (LA group n = 91, LA + H group n = 89) from June 2023 to November 2024 across four French hematological departments. The primary endpoint was patient comfort rated on a scale from 0 (no comfort) to 10 (maximum comfort), evaluated immediately after the procedure. Secondary outcomes included pain, anxiety (before and after BMB), practitioner comfort, and use of EMONO.

Results

Patient groups were well-matched at enrolment. Median comfort scores were 9 vs. 5, pain scores 2 vs.6, and post-procedure scores 1 vs.5, in the LA + H vs.LA groups, respectively, both with p < 10⁻4. Finally, the operator comfort was higher (10 vs. 7), and EMONO requirement lower (3% vs. 29%) in the LA + H group, both with p < 10⁻4.

Conclusion

These findings suggest that hypnosis significantly enhances patient comfort and key procedural parameters during BMB, warranting its consideration as addition to local anesthesia. Its integration into clinical practice may reduce the need for supplementary pharmacological interventions, including EMONO.

Trial registration

ClinicalTrials.gov Identifier NCT05178849.